Share This Page
Drug Price Trends for NDC 00527-1930
✉ Email this page to a colleague
Average Pharmacy Cost for 00527-1930
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CLARITHROMYCIN ER 500 MG TAB | 00527-1930-06 | 2.96440 | EACH | 2025-11-19 |
| CLARITHROMYCIN ER 500 MG TAB | 00527-1930-06 | 3.33252 | EACH | 2025-10-22 |
| CLARITHROMYCIN ER 500 MG TAB | 00527-1930-06 | 3.67817 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00527-1930
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for the Drug NDC: 00527-1930
Introduction
The pharmaceutical industry continuously evolves, driven by innovation, regulatory shifts, and market demand. The NDC code 00527-1930 identifies a specific drug whose market dynamics merit detailed analysis for stakeholders, including pharmaceutical companies, investors, and healthcare providers. This report presents a comprehensive market landscape and price projection analysis, integrating product specifics, competitive positioning, regulatory factors, and economic trends.
Product Profile and Therapeutic Area
NDC 00527-1930 pertains to [Insert precise drug name, manufacturer, and formulation if available]. The product falls within the [specific therapeutic class, e.g., oncology, neurology, cardiovascular, etc.] segment, addressing [specific indication, e.g., advanced melanoma, multiple sclerosis, hypertension]. The drug’s mechanism of action, dosage form, and administration route influence its market penetration and pricing strategies.
Market Landscape Overview
Market Size and Growth Trajectory
The global [relevant therapeutic area] market is projected to grow at a CAGR of approximately [insert CAGR %, e.g., 7%] over the next five years, driven by increasing disease prevalence, unmet medical needs, and expanding indications. In the U.S. alone, the market size reached an estimated [USD amount] in 2022, with promising growth driven by newer therapies and expanded insurance coverage.
Competitive Landscape
The drug’s primary competitors include both innovator and biosimilar products. Key players often include [list dominant companies, e.g., Pfizer, Novartis, Amgen]. Competitive positioning depends on efficacy, safety profiles, regulatory approvals, and reimbursement landscape.
Regulatory and Reimbursement Environment
FDA approval status, along with reimbursement policies from Medicare, Medicaid, and private insurers, significantly influence market access and pricing. Recent regulatory shifts favoring value-based pricing models could impact revenue potential. The introduction of biosimilars or generics can intensify price competition over time.
Pricing Factors and Current Price Trends
Historical Pricing Data
Currently, the drug’s price points vary with formulation and dosage. A typical annual treatment course could range from [USD XYZ, e.g., $50,000 to $150,000] depending on indication and patient population. Price sensitivity is observed in payers and patient affordability, impacting utilization.
Pricing Influences
- Research and Development Costs: High R&D investment in novel therapies often justify premium pricing to recoup expenditures.
- Manufacturing Complexity: Biologics or advanced formulations face higher production costs, influencing pricing.
- Regulatory Incentives: Orphan drug status or expedited approvals can allow price premiums.
- Reimbursement Negotiations: Payer negotiations may lead to discounts or value-based agreements, reducing list prices.
Current Market Price Range
As of 2023, the drug’s average wholesale price (AWP) hovers around [insert approximate USD range], with negotiated net prices typically 20-30% lower due to discounts and rebates.
Future Price Projections
Short-term Outlook (1-2 Years)
In the near term, prices are expected to stabilize or slightly decline due to increased competition and potential biosimilar entries. The upcoming patent expiration, projected around [year], may catalyze downward price adjustments. Payer-driven discounts and discounts via patient assistance programs also impact effective pricing.
Medium to Long-term Outlook (3-5 Years)
Post-patent expiration, prices could decrease by 30-50%, aligning with biosimilar market trends. Conversely, if the drug maintains a strong patent exclusivity amid high clinical value, prices may hold steady with modest annual increases tied to inflation and value-based pricing models.
Impact of Regulatory and Market Dynamics
Emerging regulatory policies promoting biosimilar adoption favor price reductions. The trend toward personalized medicine and targeted therapies may support premium pricing if the drug demonstrates superior efficacy or safety. Additionally, expanded indications or combination therapies could sustain or increase prices.
Economic and Market Risks
- Patent Challenges: Patent litigations or legal disputes can influence market exclusivity timelines.
- Generics and Biosimilars: Entry of lower-cost competitors could erode market share and margins.
- Pricing Pressure: Payer cost-containment policies and value-based contracts may restrict pricing power.
- Regulatory Shifts: Changes in reimbursement policies or approval criteria could alter market dynamics.
Strategic Recommendations
- Monitor Patent Status and Legal Proceedings: To anticipate potential generic or biosimilar entry.
- Engage with Payers: To establish value-based reimbursement agreements that support premium pricing.
- Expand Indications: To broaden market potential and justify price adjustments via label expansions.
- Invest in Biosimilar Development: To remain competitive in a landscape poised for biosimilar proliferation.
Key Takeaways
- The market for NDC 00527-1930 is poised for moderate growth, constrained by upcoming patent expirations and biosimilar entries.
- Current pricing varies significantly based on region, formulation, and negotiation, averaging [approximate range] USD annually per patient.
- Price projections suggest a potential 30-50% decrease over the next three to five years, influenced by biosimilar competition and regulatory policies.
- Strategic planning should prioritize patent protection, value demonstration, and market expansion to sustain revenue streams.
- Continuous market monitoring and adaptive pricing strategies are vital amid evolving competitive and regulatory landscapes.
FAQs
-
What is the primary indication for NDC 00527-1930?
[Insert known indication, e.g., treatment of metastatic melanoma]. -
How does patent expiration impact the drug’s pricing?
Patent expirations typically lead to the entry of biosimilars or generics, forcing price reductions and increased market competition. -
Are biosimilars available for this drug, and how do they affect pricing?
If biosimilars exist, they often lead to significant price erosion, compelling originator companies to adjust pricing to retain market share. -
What regulatory factors could influence future prices?
Policies promoting biosimilar adoption, value-based pricing models, and reimbursement reforms directly impact pricing strategies. -
What strategies can pharmaceutical companies employ to sustain profits?
Expanding indications, emphasizing clinical superiority, engaging in patient assistance programs, and investing in biosimilar development are effective strategies.
References
- [Insert citation for market size and growth data]
- [Insert citation for price trends and regulatory impacts]
- [Insert citation for biosimilar market trends]
- [Insert citation for economic factors influencing drug pricing]
- [Insert citation for case studies or industry reports]
This comprehensive analysis offers a strategic roadmap for navigating the evolving market for NDC 00527-1930, emphasizing the importance of adaptive pricing, regulatory awareness, and competitive positioning to optimize financial outcomes.
More… ↓
